Buscar
Mostrando ítems 1-10 de 310
Long-term stability studies on protection against Newcastle disease by commercial live vaccine used in Brazil
(Academic Press Ltd Elsevier B.V. Ltd, 2009-08-01)
The thermostability (TS) and efficacy offered by live vaccines against Newcastle disease strains B 1, La Sota, VG-GA and Ulster, produced or imported by four Brazilian laboratories, were evaluated during their validity ...
Effectiveness and duration of a second COVID-19 vaccine boosterEffectiveness and duration of a second COVID-19 vaccine booster
(2022)
Using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluated the effectiveness against COVID-19 related ICU admissions and death of mRNA-based second vaccine boosters for four different ...
Recent advances in DNA vaccines for autoimmune diseases
(Expert Reviews, 2009-02-01)
Vaccination is one of the most powerful health tools available owing to its ability to confer protection against various diseases. The long-term impact of such protection in terms of public-health savings is nearly ...
Recent advances in DNA vaccines for autoimmune diseases
(Expert Reviews, 2009-02-01)
Vaccination is one of the most powerful health tools available owing to its ability to confer protection against various diseases. The long-term impact of such protection in terms of public-health savings is nearly ...
Long-term stability studies on protection against Newcastle disease by commercial live vaccine used in Brazil
(Academic Press Ltd Elsevier B.V. Ltd, 2009-08-01)
The thermostability (TS) and efficacy offered by live vaccines against Newcastle disease strains B 1, La Sota, VG-GA and Ulster, produced or imported by four Brazilian laboratories, were evaluated during their validity ...
Long-term stability studies on protection against Newcastle disease by commercial live vaccine used in Brazil
(Academic Press Ltd- Elsevier Science LtdLondonInglaterra, 2009)
Long-term stability studies on protection against Newcastle disease by commercial live vaccine used in Brazil
(Academic Press Ltd Elsevier B.V. Ltd, 2014)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
(Landes BioscienceAustinEUA, 2012)